Hjem › Akut myeloid leukæmi › Massachusetts
Akut myeloid leukæmi kliniske forsøg i Massachusetts
45 studier for Akut myeloid leukæmi søger deltagere på steder i Massachusetts.
Byer i Massachusetts
Officiel studietekst (engelsk)
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Dana-Farber Cancer Institute, Boston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT06484062Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- Lahey Clinic, Burlington
- og 1 flere
RekruttererFase 2
Alder 18 til 59 · Alle køn · Opdateret 28. sep. 2026 · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Dana Farber Cancer Institute, Boston
- Beth Israel Deaconess Medical Center, Boston
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- og 1 flere
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT05564390Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- og 2 flere
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT06317649Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- Tufts Medical Center, Boston
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT06672146Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- og 2 flere
RekruttererFase 2
Alder 18 til 59 · Alle køn · Opdateret 22. sep. 2026 · NCT05554406A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
- Dana-Farber Cancer Center, Boston
RekruttererFase 1/2
Alder 12 og opefter · Alle køn · Opdateret 18. sep. 2026 · NCT06284486A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
- UMass Memorial Medical Center - University Campus, Worcester
RekruttererFase 3
6 Months – 21 Years · Alle køn · Opdateret 17. sep. 2026 · NCT04293562(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- Dana-Farber Cancer Institute, Boston
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 15. sep. 2026 · NCT04996875Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- Dana-Farber Cancer Institute, Boston
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 14. sep. 2026 · NCT03471260Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Massachusetts General Hospital, Boston
RekruttererFase 1/2
Alder 12 og opefter · Alle køn · Opdateret 3. sep. 2026 · NCT04588922CIML NK Cells With Venetoclax for AML
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 28. aug. 2026 · NCT06152809Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
RekruttererFase 1
Alder 18 til 90 · Alle køn · Opdateret 26. aug. 2026 · NCT07439211Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
- Dana-Farber Cancer Institute, Boston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 25. aug. 2026 · NCT06533761A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
- Dana-Farber Cancer Institute, Boston
RekruttererFase 1
Alder 18 til 75 · Alle køn · Opdateret 25. aug. 2026 · NCT05886049The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Dana-Farber Cancer Institute, Boston
RekruttererFase 1/2
Op til 22 år · Alle køn · Opdateret 25. aug. 2026 · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Dana-Farber Cancer Institute, Boston
RekruttererFase 3
29 Days – 21 Years · Alle køn · Opdateret 24. aug. 2026 · NCT05183035Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Massachusetts, Worcester
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 20. aug. 2026 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Beth Israel Deaconess Medical Center, Boston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 20. aug. 2026 · NCT06001788A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
- Brigham and Women's Hospital, Boston
RekruttererFase 1Frivillige med god helbredstilstand velkomne
Alder 18 til 75 · Alle køn · Opdateret 28. jul. 2026 · NCT07020533A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Tufts Medical Center, Boston
- Beth Israel Deaconess, Boston
- Dana Farber Cancer Institute, Boston
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 6. jul. 2026 · NCT01351545Ivosidenib as Post-HSCT Maintenance for AML
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 18. jun. 2026 · NCT06707493A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
RekruttererFase 1
Alder 12 og opefter · Alle køn · Opdateret 17. jun. 2026 · NCT04024761Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 17. jun. 2026 · NCT06138587SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Dana Farber Cancer Institute, Boston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 17. jun. 2026 · NCT03113643Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
- Dana-Farber Cancer Institute, Boston
- Dana Farber Cancer Institute at St. Elizabeth's, Brighton
- Dana Farber Cancer Institute at Merrimack Valley, Methuen
- og 2 flere
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 7. maj 2026 · NCT02269592Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML
- Beth Israel Deaconess Medical Center, Boston
RekruttererFase 1
Alle aldre · Alle køn · Opdateret 5. maj 2026 · NCT07374029Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- Dana Farber Cancer Institute, Boston
RekruttererFase 1
Alder 13 og opefter · Alle køn · Opdateret 5. maj 2026 · NCT04771572A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Dana-Farber Cancer Institute, Boston
RekruttererFase 2/3
Alder 18 og opefter · Alle køn · Opdateret 30. apr. 2026 · NCT04256317BCL2i CLAG-M in R/R Acute Myeloid Leukemia
- Dana-Farber Cancer Institute, Boston
RekruttererFase 2
Alder 18 til 80 · Alle køn · Opdateret 1. apr. 2026 · NCT06660368Revumenib in Combination With 7+3 + Midostaurin in AML
- Dana-Farber Cancer Institute, Boston
RekruttererFase 1
Alder 18 til 75 · Alle køn · Opdateret 25. mar. 2026 · NCT06313437A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Massachusetts General Hospital, Boston
RekruttererFase 1/2
Alder 12 og opefter · Alle køn · Opdateret 24. mar. 2026 · NCT04988555Ziftomenib Maintenance Post Allo-HCT
- Massachusetts General Hospital, Boston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 19. mar. 2026 · NCT06440135A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Dana-Farber Cancer Institute, Boston
RekruttererFase 2
Alder 18 til 66 · Alle køn · Opdateret 17. mar. 2026 · NCT06859424A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
- Dana Farber Cancer Institute, Boston
RekruttererFase 1
Alder 12 og opefter · Alle køn · Opdateret 16. mar. 2026 · NCT06994676A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Massachusetts General Hospital, Boston
- UMass Chan Medical School, Worcester
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 13. mar. 2026 · NCT05735184CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
- DFCI/BWH Brigham and Women's Hospital, Boston
RekruttererFase 2Frivillige med god helbredstilstand velkomne
Alder 18 til 75 · Alle køn · Opdateret 10. mar. 2026 · NCT06059391A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
- DFCI, Boston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 9. feb. 2026 · NCT06950034A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 5. feb. 2026 · NCT07148180Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.